No human clinical trials yet so you will need to depend on your doctors analysis if this is worth trying.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=73295#.UXFxond9CpI
BioTime Inc. (NYSE MKT: BTX) today announced that it has entered into
an exclusive license agreement with the University of California Los
Angeles (UCLA) for novel technology related to the treatment of stroke.
The licensed technology developed in the laboratories of Tom Carmichael
MD PhD of UCLA’s Department of Neurology at the David Geffen School of
Medicine uses one of BioTime’s HyStem® hydrogels to
deliver locally released growth factors to improve recovery from stroke.
Pre-clinical studies have demonstrated that the localized delivery of
growth factors such as brain-derived neurotrophic factor (BDNF) results
in a statistically significant improvement in post-stroke motor function
in a murine model of ischemic stroke.
Concurrent with the
execution of this exclusive license agreement BioTime has entered into a
Sponsored Research Agreement with UCLA to support on-going pre-clinical
work in Dr. Carmichael’s laboratory to advance the understanding of
this technology and develop data in support for the potential filing of
an Investigational New Drug Application (IND) for human clinical trails.
No comments:
Post a Comment